A follow-up study supported the idea that RUNX1 mainly acts as a tumor suppressor in ER+ breast cancer, and it can exert oncogenic effects by suppressing the estrogen-mediated inhibition of AXIN1 and activation of the Wnt/β-catenin signaling pathway [41]. Here, RUNX1 is linked to breast carcinoma.